PL3119794T3 - Preparat zawierający prolek gemcytabiny - Google Patents

Preparat zawierający prolek gemcytabiny

Info

Publication number
PL3119794T3
PL3119794T3 PL15733498T PL15733498T PL3119794T3 PL 3119794 T3 PL3119794 T3 PL 3119794T3 PL 15733498 T PL15733498 T PL 15733498T PL 15733498 T PL15733498 T PL 15733498T PL 3119794 T3 PL3119794 T3 PL 3119794T3
Authority
PL
Poland
Prior art keywords
gemcitabine
prodrug
formulation
Prior art date
Application number
PL15733498T
Other languages
English (en)
Inventor
Hugh GRIFFITH
Gordon KENNOVIN
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411253.6A external-priority patent/GB201411253D0/en
Priority claimed from GBGB1417646.5A external-priority patent/GB201417646D0/en
Application filed by NuCana plc filed Critical NuCana plc
Publication of PL3119794T3 publication Critical patent/PL3119794T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL15733498T 2014-06-25 2015-06-25 Preparat zawierający prolek gemcytabiny PL3119794T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2050MU2014 2014-06-25
GBGB1411253.6A GB201411253D0 (en) 2014-06-25 2014-06-25 Prodrug
GBGB1417646.5A GB201417646D0 (en) 2014-10-06 2014-10-06 Formulations of phosphate derivatives
EP15733498.8A EP3119794B1 (en) 2014-06-25 2015-06-25 Formulation comprising a gemcitabine-prodrug
PCT/GB2015/051858 WO2015198059A1 (en) 2014-06-25 2015-06-25 Formulation comprising a gemcitabine-prodrug

Publications (1)

Publication Number Publication Date
PL3119794T3 true PL3119794T3 (pl) 2018-04-30

Family

ID=53499028

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15733498T PL3119794T3 (pl) 2014-06-25 2015-06-25 Preparat zawierający prolek gemcytabiny

Country Status (30)

Country Link
US (4) US10117888B2 (pl)
EP (2) EP3269391A1 (pl)
JP (3) JP6855248B2 (pl)
KR (2) KR102421929B1 (pl)
CN (2) CN110882268A (pl)
AU (2) AU2015278900B2 (pl)
BR (1) BR112016025787B1 (pl)
CA (1) CA2944966C (pl)
CL (1) CL2016003261A1 (pl)
CY (1) CY1119772T1 (pl)
DK (1) DK3119794T3 (pl)
EA (1) EA033046B1 (pl)
ES (1) ES2655820T3 (pl)
HK (1) HK1244437A1 (pl)
HR (1) HRP20180007T1 (pl)
HU (1) HUE036011T2 (pl)
IL (2) IL248345B (pl)
LT (1) LT3119794T (pl)
MX (2) MX373942B (pl)
MY (1) MY186584A (pl)
NO (1) NO3119794T3 (pl)
PH (1) PH12016502552A1 (pl)
PL (1) PL3119794T3 (pl)
PT (1) PT3119794T (pl)
RS (1) RS56752B1 (pl)
SG (1) SG11201608809RA (pl)
SI (1) SI3119794T1 (pl)
SM (1) SMT201800041T1 (pl)
TW (2) TWI765176B (pl)
WO (1) WO2015198059A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ES2569185T3 (es) 2011-03-01 2016-05-09 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
HRP20191461T1 (hr) 2014-11-28 2019-11-15 NuCana plc Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
CN106478753A (zh) 2015-09-16 2017-03-08 博瑞生物医药(苏州)股份有限公司 一种nuc‑1031单一异构体的制备方法和用途
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药(苏州)股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106543252A (zh) 2015-09-16 2017-03-29 博瑞生物医药(苏州)股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
CA3007347C (en) 2015-12-11 2020-08-04 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
US11000490B2 (en) 2016-11-02 2021-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
WO2019018769A1 (en) 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN109956986B (zh) 2017-12-22 2021-04-27 浙江柏拉阿图医药科技有限公司 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用
WO2023076878A1 (en) * 2021-10-26 2023-05-04 Emphascience Inc. Ready-to-dilute formulation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
ES2172303T3 (es) 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
HK1053126A1 (zh) 1999-07-22 2003-10-10 新生物生物公司 酶催化的治疗活化
CN1181829C (zh) * 2000-11-03 2004-12-29 中国人民解放军军事医学科学院附属医院 吉西他滨溶液制剂
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP1845787B1 (en) 2005-01-27 2015-04-15 Erimos Pharmaceuticals LLC Formulations for injection of catecholic butanes, including ndga compounds, into animals
KR101478164B1 (ko) 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
EP1913962A1 (en) * 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
WO2011008985A2 (en) * 2009-07-15 2011-01-20 Georgia Tech Research Corporation Methods and compositions for improved delivery of therapeutic and diagnostic agents
RU2012125350A (ru) * 2009-11-20 2013-12-27 Клавис Фарма Аса Парентеральные препараты производных гемцитабина
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
KR101231925B1 (ko) * 2010-10-27 2013-02-08 씨제이제일제당 (주) 젬시타빈의 전구약물 및 이의 제조방법
WO2013107515A1 (en) * 2012-01-20 2013-07-25 Okapi Sciences Nv Eye drop composition
US9447137B2 (en) * 2012-11-07 2016-09-20 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine aryl amide analogs
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
JP2017504572A (ja) 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
US9834577B2 (en) 2014-07-22 2017-12-05 Laurus Labs Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN107835687A (zh) 2015-05-14 2018-03-23 努卡那有限公司 癌症治疗
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
CA3007347C (en) 2015-12-11 2020-08-04 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
SI3393478T1 (sl) 2015-12-23 2020-07-31 NuCana plc Kombinacijska terapija
KR102566461B1 (ko) 2015-12-23 2023-08-14 뉴카나 피엘씨 조합 요법
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Also Published As

Publication number Publication date
AU2019204557A1 (en) 2019-07-18
CA2944966C (en) 2022-10-25
JP2022031659A (ja) 2022-02-22
CA2944966A1 (en) 2015-12-30
MX373942B (es) 2020-07-13
EP3269391A1 (en) 2018-01-17
AU2019204557B2 (en) 2020-08-27
MX388313B (es) 2025-03-19
TW201613611A (en) 2016-04-16
BR112016025787A2 (pt) 2017-08-15
SMT201800041T1 (it) 2018-03-08
HK1244437A1 (en) 2018-08-10
CY1119772T1 (el) 2018-06-27
US20190022118A1 (en) 2019-01-24
US20220031727A1 (en) 2022-02-03
IL248345A0 (en) 2016-11-30
AU2015278900A1 (en) 2016-10-27
US10786523B2 (en) 2020-09-29
EP3119794B1 (en) 2017-10-11
NZ725009A (en) 2021-02-26
JP6855248B2 (ja) 2021-04-07
TWI765176B (zh) 2022-05-21
DK3119794T3 (en) 2018-01-22
JP2017519022A (ja) 2017-07-13
CN106470672B (zh) 2019-11-05
US11707477B2 (en) 2023-07-25
MX2020004054A (es) 2021-11-30
WO2015198059A1 (en) 2015-12-30
JP7329025B2 (ja) 2023-08-17
SI3119794T1 (en) 2018-02-28
HUE036011T2 (hu) 2018-06-28
US11040051B2 (en) 2021-06-22
LT3119794T (lt) 2018-02-12
MX2016015629A (es) 2017-08-02
IL276199B (en) 2022-04-01
BR112016025787B1 (pt) 2022-12-13
JP2020079255A (ja) 2020-05-28
JP6970221B2 (ja) 2021-11-24
SG11201608809RA (en) 2016-11-29
US20170095498A1 (en) 2017-04-06
AU2015278900B2 (en) 2019-04-04
US10117888B2 (en) 2018-11-06
ES2655820T3 (es) 2018-02-21
CN110882268A (zh) 2020-03-17
IL276199A (en) 2020-09-30
TWI674097B (zh) 2019-10-11
US20200397810A1 (en) 2020-12-24
EA201692422A1 (ru) 2017-04-28
PT3119794T (pt) 2018-01-15
HRP20180007T1 (hr) 2018-02-23
CN106470672A (zh) 2017-03-01
KR20220104270A (ko) 2022-07-26
EA033046B1 (ru) 2019-08-30
TW201945007A (zh) 2019-12-01
PH12016502552A1 (en) 2017-04-10
EP3119794A1 (en) 2017-01-25
CL2016003261A1 (es) 2017-10-06
MY186584A (en) 2021-07-28
KR20170042501A (ko) 2017-04-19
KR102421929B1 (ko) 2022-07-15
IL248345B (en) 2020-10-29
RS56752B1 (sr) 2018-04-30
NO3119794T3 (pl) 2018-03-10

Similar Documents

Publication Publication Date Title
IL276199B (en) The composition containing gemcitabine-meter drug
ZA201608424B (en) A micellar nanocomplex
GB201407934D0 (en) Formulation
PL3107946T3 (pl) Poliizomocznik
IL248174A0 (en) Agrochemical formulations
IL248835A0 (en) A preparation of ciritinib
GB201402448D0 (en) Novel formulation
GB201402247D0 (en) A footgauge
IL251362A0 (en) formulation
GB201511301D0 (en) Formulation
GB2517601B (en) A plinth
GB201518909D0 (en) A formulation
GB201511682D0 (en) A case
GB201416247D0 (en) A formulation
GB201416536D0 (en) Formulation
GB201416274D0 (en) Formulation
GB201412754D0 (en) Formulation
GB201404773D0 (en) Formulation
GB201404865D0 (en) A Hydrogenerator
GB201400958D0 (en) n/a
GB201400532D0 (en) Metix limited COREMED A
GB201419012D0 (en) A composition
GB201414050D0 (en) A composition
GB201411681D0 (en) Concept a
GB201404151D0 (en) A duster